Nabsys

Nabsys is a private company commercializing the OhmX Platform, an electronic genome mapping system for high-resolution structural variant (SV) detection. The technology addresses a critical gap in genomic analysis by providing an orthogonal, cost-effective method to validate and discover SVs, which are major contributors to genetic disease and cancer. Its primary business model is the sale of instruments, consumables, and software to research institutions, positioning it in the genomics tools and diagnostics sector. The company is actively generating revenue through product sales and is focused on expanding applications in cancer research, rare disease, and cell/gene therapy.

Electronic Genome Mapping (EGM) using electronic nano-detectors to create high-resolution maps of long DNA molecules for structural variant detection down to 300bp.

Nabsys competes in the genomic structural variant analysis space. Primary competitors include Bionano Genomics (optical genome mapping) and sequencing companies (Illumina, PacBio, Oxford Nanopore) that are continuously improving their own SV detection capabilities. Nabsys differentiates on resolution (down to 300bp), benchtop simplicity, cost-positioning for orthogonal validation, and its electronic detection method.